

DATASHEET

Abbexa Ltd, Innovation Centre, Cambridge Science Park, Cambridge, CB4 0EY, UK Telephone: +44 (0) 1223 755950 - Fax: +44 (0) 1223 755951 - E-Mail: info@abbexa.com

GLRX5 siRNA Catalogue No.:abx918036

siRNA to inhibit GLRX5 expression using RNA interference.

This product is provided as two 5 nmol vials (10 nmol), three 5 nmol vials (15 nmol) or 2x three 5 nmol vials (30 nmol) of lyophilized siRNA oligo duplexes. Each vial contains slightly different sequences to ensure full knockout of the gene. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. The siRNA oligos are also chemically modified (2'-OMe) for increased stability and enhanced knockdown in vitro and in vivo.

Target:	GLRX5
Reactivity:	Human
Host:	Synthetic
Tested Applications: RNAi	
Purity:	> 97%
Form:	Lyophilized
Specificity:	GLRX5 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Storage:	Shipped at 4 °C. Store at -20 °C for up to one year.
Swiss Prot:	<u>Q86SX6</u>
GenelD:	<u>51218</u>
Gene Symbol:	GLRX5
Directions for use: Quality Control:	 Transfect with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. Each vial is suitable for 250 transfections in a 24 well plate (20 pmol for each well). Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed



Abbexa Ltd, Innovation Centre, Cambridge Science Park, Cambridge, CB4 0EY, UK Telephone: +44 (0) 1223 755950 - Fax: +44 (0) 1223 755951 - E-Mail: info@abbexa.com DATASHEET

Note: This product is for research use only.